Cargando…

Iguratimod suppresses Tfh cell differentiation in primary Sjögren’s syndrome patients through inhibiting Akt/mTOR/STAT3 signaling

BACKGROUND: Iguratimod (IGU) reduces hypergammaglobulinemia and disease activity in pSS (primary Sjögren’s syndrome) patients. However, the therapeutical mechanism of IGU for pSS remains largely unknown. This study aimed to investigate the regulation of Tfh cell differentiation by IGU in pSS patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lyu, Taibiao, Jiang, Hui, Zeng, Liuting, Liu, Suying, He, Chengmei, Luo, Chaowen, Qiao, Lin, Zhao, Yan, Chen, Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463648/ https://www.ncbi.nlm.nih.gov/pubmed/37608388 http://dx.doi.org/10.1186/s13075-023-03109-4

Ejemplares similares

EZH2 Promotes T Follicular Helper Cell Differentiation Through Enhancing STAT3 Phosphorylation in Patients With Primary Sjögren’s Syndrome
por: He, Chengmei, et al.
Publicado: (2022)

A Systematic Review and Meta-Analysis of 19 Randomized Controlled Trials of Iguratimod Combined With Other Therapies for Sjogren’s Syndrome
por: Zeng, Liuting, et al.
Publicado: (2022)

LncRNA LYPLAL1-AS1 rejuvenates human adipose-derived mesenchymal stem cell senescence via transcriptional MIRLET7B inactivation
por: Yang, Yanlei, et al.
Publicado: (2022)

Long Non-coding RNA Regulation of Mesenchymal Stem Cell Homeostasis and Differentiation: Advances, Challenges, and Perspectives
por: Yang, Yanlei, et al.
Publicado: (2021)

PI3K/AKT/mTOR Signaling Pathway Is Downregulated by Runzaoling (RZL) in Sjögren's Syndrome
por: Zeng, Ping, et al.
Publicado: (2022)

The Paradox of Akt-mTOR Interactions
por: Vadlakonda, Lakshmipathi, et al.
Publicado: (2013)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Research progress on the clinical application and mechanism of iguratimod in the treatment of autoimmune diseases and rheumatic diseases
por: Long, Zhiyong, et al.
Publicado: (2023)

Effectiveness and Safety of Iguratimod in Treating Primary Sjögren’s Syndrome: A Systematic Review and Meta-Analysis
por: Pu, Jincheng, et al.
Publicado: (2021)

Iguratimod in treatment of primary Sjögren’s syndrome concomitant with autoimmune hemolytic anemia: A case report
por: Zhang, Juan, et al.
Publicado: (2022)

Arnicolide D Inhibits Triple Negative Breast Cancer Cell Proliferation by Suppression of Akt/mTOR and STAT3 Signaling Pathways
por: Qu, Zhao, et al.
Publicado: (2020)

Dihydroartemisinin Induces Endothelial Cell Autophagy through Suppression of the Akt/mTOR Pathway
por: Liu, Jing, et al.
Publicado: (2019)

Akt and mTOR in B Cell Activation and Differentiation
por: Limon, Jose J., et al.
Publicado: (2012)

Akt and mTOR mediate programmed necrosis in neurons
por: Liu, Q, et al.
Publicado: (2014)

The Cytotoxic Effect of Curcumin in Rhabdomyosarcoma Is Associated with the Modulation of AMPK, AKT/mTOR, STAT, and p53 Signaling
por: Salucci, Sara, et al.
Publicado: (2023)

The Effect and Safety of Iguratimod Combined With Methotrexate on Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Based on a Randomized Controlled Trial
por: Zeng, Liuting, et al.
Publicado: (2022)

Autophagy activation promotes bevacizumab resistance in glioblastoma by suppressing Akt/mTOR signaling pathway
por: Huang, He, et al.
Publicado: (2018)

Suppression of Akt-mTOR pathway rescued the social behavior in Cntnap2-deficient mice
por: Xing, Xiaoliang, et al.
Publicado: (2019)

Glycolysis is suppressed by DCZ0801-induced inactivation of the Akt/mTOR pathway in Multiple Myeloma
por: Feng, Qilin, et al.
Publicado: (2020)

GABARAP suppresses EMT and breast cancer progression via the AKT/mTOR signaling pathway
por: Liu, Ying, et al.
Publicado: (2021)

Hedyotis diffusa Willd. Suppresses Hepatocellular Carcinoma via Downregulating AKT/mTOR Pathways
por: Huang, Lingli, et al.
Publicado: (2021)

Rhaponticin suppresses osteosarcoma through the inhibition of PI3K-Akt-mTOR pathway
por: Mickymaray, Suresh, et al.
Publicado: (2021)

Efficacy and safety of Iguratimod in the treatment of Ankylosing Spondylitis: A systematic review and meta-analysis of randomized controlled trials
por: Long, Zhiyong, et al.
Publicado: (2023)

Inhibition of the AKT/mTOR pathway negatively regulates PTEN expression via miRNAs: Effect of Akt/mTOR inhibition on PTEN expression
por: Wan, Linyan, et al.
Publicado: (2022)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Linalool Impress Colorectal Cancer Deterioration by Mediating AKT/mTOR and JAK2/STAT3 Signaling Pathways
por: Hou, Min, et al.
Publicado: (2022)

Feedback activation of STAT3 limits the response to PI3K/AKT/mTOR inhibitors in PTEN-deficient cancer cells
por: Wang, Jian, et al.
Publicado: (2021)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

Olfactory Ecto-mesenchymal Stem Cell-derived Exosomes Ameliorate Murine Sjögren’s Syndrome via Suppressing Tfh Cell Response
por: Rui, Ke, et al.
Publicado: (2022)

Scutellarin suppresses proliferation and promotes apoptosis in A549 lung adenocarcinoma cells via AKT/mTOR/4EBP1 and STAT3 pathways
por: Cao, Pikun, et al.
Publicado: (2019)

Role of the mTOR pathway in minor salivary gland changes in Sjogren’s syndrome and systemic sclerosis
por: Soypaçacı, Zeki, et al.
Publicado: (2018)

Rapamycin suppresses postnatal muscle hypertrophy induced by myostatin-inhibition accompanied by transcriptional suppression of the Akt/mTOR pathway
por: Choi, Dong hyuck, et al.
Publicado: (2019)

STAT3 and mTOR: co-operating to drive HIF and angiogenesis
por: Dodd, Kayleigh M., et al.
Publicado: (2015)

Preparation of a Major Metabolite of Iguratimod and Simultaneous Assay of Iguratimod and Its Metabolite by HPLC in Rat Plasma
por: Han, Jun-ping, et al.
Publicado: (2019)

Histone Deacetylase Inhibitors Inhibit the Proliferation of Gallbladder Carcinoma Cells by Suppressing AKT/mTOR Signaling
por: Zhang, Peng, et al.
Publicado: (2015)

Valproic acid induces autophagy by suppressing the Akt/mTOR pathway in human prostate cancer cells
por: Xia, Qinghua, et al.
Publicado: (2016)

MAF1 suppresses AKT‐mTOR signaling and liver cancer through activation of PTEN transcription
por: Li, Yue, et al.
Publicado: (2016)

Deoxyshikonin Inhibits Viability and Glycolysis by Suppressing the Akt/mTOR Pathway in Acute Myeloid Leukemia Cells
por: Wu, Huijuan, et al.
Publicado: (2020)

ARHGAP25 Inhibits Pancreatic Adenocarcinoma Growth by Suppressing Glycolysis via AKT/mTOR Pathway
por: Huang, Wen-Kuan, et al.
Publicado: (2021)

MK-2206 Alleviates Renal Fibrosis by Suppressing the Akt/mTOR Signaling Pathway In Vivo and In Vitro
por: Chen, Meiling, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k7fjjiphtrhc19bmoi4vjjd3s0